nodes	percent_of_prediction	percent_of_DWPC	metapath
Captopril—ACE—polycystic ovary syndrome	0.606	1	CbGaD
Captopril—MMP2—tunica intima—polycystic ovary syndrome	0.0208	0.118	CbGeAlD
Captopril—MMP9—tunica intima—polycystic ovary syndrome	0.0181	0.103	CbGeAlD
Captopril—REN—urine—polycystic ovary syndrome	0.0111	0.0631	CbGeAlD
Captopril—ACE—tunica intima—polycystic ovary syndrome	0.00963	0.0546	CbGeAlD
Captopril—F2—urine—polycystic ovary syndrome	0.00776	0.044	CbGeAlD
Captopril—ACE—urine—polycystic ovary syndrome	0.00474	0.0269	CbGeAlD
Captopril—LTA4H—embryo—polycystic ovary syndrome	0.00466	0.0264	CbGeAlD
Captopril—LTA4H—adrenal cortex—polycystic ovary syndrome	0.00382	0.0217	CbGeAlD
Captopril—LTA4H—endometrium—polycystic ovary syndrome	0.00341	0.0193	CbGeAlD
Captopril—MMP2—embryo—polycystic ovary syndrome	0.0033	0.0187	CbGeAlD
Captopril—LTA4H—uterus—polycystic ovary syndrome	0.00314	0.0178	CbGeAlD
Captopril—LTA4H—pituitary gland—polycystic ovary syndrome	0.00308	0.0175	CbGeAlD
Captopril—LTA4H—adipose tissue—polycystic ovary syndrome	0.00307	0.0174	CbGeAlD
Captopril—REN—adrenal cortex—polycystic ovary syndrome	0.00295	0.0167	CbGeAlD
Captopril—MMP9—embryo—polycystic ovary syndrome	0.00287	0.0163	CbGeAlD
Captopril—LTA4H—adrenal gland—polycystic ovary syndrome	0.00276	0.0156	CbGeAlD
Captopril—MMP2—adrenal cortex—polycystic ovary syndrome	0.00271	0.0154	CbGeAlD
Captopril—REN—endometrium—polycystic ovary syndrome	0.00263	0.0149	CbGeAlD
Captopril—LTA4H—female gonad—polycystic ovary syndrome	0.00257	0.0146	CbGeAlD
Captopril—LTA4H—vagina—polycystic ovary syndrome	0.00255	0.0145	CbGeAlD
Captopril—MMP2—endometrium—polycystic ovary syndrome	0.00242	0.0137	CbGeAlD
Captopril—LTA4H—endocrine gland—polycystic ovary syndrome	0.00239	0.0136	CbGeAlD
Captopril—REN—pituitary gland—polycystic ovary syndrome	0.00238	0.0135	CbGeAlD
Captopril—CYP2D6—urine—polycystic ovary syndrome	0.00232	0.0132	CbGeAlD
Captopril—MMP2—uterus—polycystic ovary syndrome	0.00223	0.0126	CbGeAlD
Captopril—MMP2—pituitary gland—polycystic ovary syndrome	0.00219	0.0124	CbGeAlD
Captopril—MMP2—adipose tissue—polycystic ovary syndrome	0.00218	0.0124	CbGeAlD
Captopril—REN—adrenal gland—polycystic ovary syndrome	0.00213	0.0121	CbGeAlD
Captopril—MMP9—endometrium—polycystic ovary syndrome	0.0021	0.0119	CbGeAlD
Captopril—REN—female gonad—polycystic ovary syndrome	0.00198	0.0112	CbGeAlD
Captopril—MMP2—adrenal gland—polycystic ovary syndrome	0.00196	0.0111	CbGeAlD
Captopril—MMP9—uterus—polycystic ovary syndrome	0.00194	0.011	CbGeAlD
Captopril—MMP9—adipose tissue—polycystic ovary syndrome	0.0019	0.0108	CbGeAlD
Captopril—Epigastric discomfort—Metformin—polycystic ovary syndrome	0.00185	0.107	CcSEcCtD
Captopril—REN—endocrine gland—polycystic ovary syndrome	0.00184	0.0105	CbGeAlD
Captopril—Enalapril—ACE—polycystic ovary syndrome	0.00184	1	CrCbGaD
Captopril—MMP2—female gonad—polycystic ovary syndrome	0.00182	0.0103	CbGeAlD
Captopril—MMP2—vagina—polycystic ovary syndrome	0.00181	0.0103	CbGeAlD
Captopril—Acidosis—Metformin—polycystic ovary syndrome	0.00175	0.102	CcSEcCtD
Captopril—MMP9—adrenal gland—polycystic ovary syndrome	0.0017	0.00965	CbGeAlD
Captopril—MMP2—endocrine gland—polycystic ovary syndrome	0.0017	0.00962	CbGeAlD
Captopril—MMP9—female gonad—polycystic ovary syndrome	0.00159	0.00899	CbGeAlD
Captopril—SLC15A1—endometrium—polycystic ovary syndrome	0.00156	0.00887	CbGeAlD
Captopril—ACE—embryo—polycystic ovary syndrome	0.00153	0.00869	CbGeAlD
Captopril—F2—adrenal gland—polycystic ovary syndrome	0.00148	0.00842	CbGeAlD
Captopril—MMP9—endocrine gland—polycystic ovary syndrome	0.00147	0.00836	CbGeAlD
Captopril—F2—female gonad—polycystic ovary syndrome	0.00138	0.00785	CbGeAlD
Captopril—F2—endocrine gland—polycystic ovary syndrome	0.00129	0.0073	CbGeAlD
Captopril—SLC15A1—vagina—polycystic ovary syndrome	0.00117	0.00665	CbGeAlD
Captopril—ACE—endometrium—polycystic ovary syndrome	0.00112	0.00636	CbGeAlD
Captopril—SLC15A1—endocrine gland—polycystic ovary syndrome	0.0011	0.00622	CbGeAlD
Captopril—ACE—pituitary gland—polycystic ovary syndrome	0.00101	0.00575	CbGeAlD
Captopril—ACE—adipose tissue—polycystic ovary syndrome	0.00101	0.00573	CbGeAlD
Captopril—ALB—adrenal gland—polycystic ovary syndrome	0.000947	0.00537	CbGeAlD
Captopril—ACE—adrenal gland—polycystic ovary syndrome	0.000906	0.00514	CbGeAlD
Captopril—ACE—female gonad—polycystic ovary syndrome	0.000845	0.00479	CbGeAlD
Captopril—ACE—endocrine gland—polycystic ovary syndrome	0.000786	0.00446	CbGeAlD
Captopril—Pancreatitis—Metformin—polycystic ovary syndrome	0.000597	0.0346	CcSEcCtD
Captopril—Angina pectoris—Metformin—polycystic ovary syndrome	0.000594	0.0344	CcSEcCtD
Captopril—Neutropenia—Metformin—polycystic ovary syndrome	0.00057	0.033	CcSEcCtD
Captopril—ABCB1—embryo—polycystic ovary syndrome	0.000539	0.00306	CbGeAlD
Captopril—Rhinitis—Metformin—polycystic ovary syndrome	0.000489	0.0283	CcSEcCtD
Captopril—Hepatitis—Metformin—polycystic ovary syndrome	0.000488	0.0283	CcSEcCtD
Captopril—Flushing—Metformin—polycystic ovary syndrome	0.000453	0.0262	CcSEcCtD
Captopril—ABCB1—adrenal cortex—polycystic ovary syndrome	0.000442	0.00251	CbGeAlD
Captopril—Dysgeusia—Metformin—polycystic ovary syndrome	0.000416	0.0241	CcSEcCtD
Captopril—CYP2D6—female gonad—polycystic ovary syndrome	0.000414	0.00235	CbGeAlD
Captopril—Vision blurred—Metformin—polycystic ovary syndrome	0.0004	0.0232	CcSEcCtD
Captopril—ABCB1—endometrium—polycystic ovary syndrome	0.000395	0.00224	CbGeAlD
Captopril—Ill-defined disorder—Metformin—polycystic ovary syndrome	0.000394	0.0228	CcSEcCtD
Captopril—CYP2D6—endocrine gland—polycystic ovary syndrome	0.000385	0.00218	CbGeAlD
Captopril—Malaise—Metformin—polycystic ovary syndrome	0.000383	0.0222	CcSEcCtD
Captopril—Syncope—Metformin—polycystic ovary syndrome	0.000381	0.0221	CcSEcCtD
Captopril—Palpitations—Metformin—polycystic ovary syndrome	0.000375	0.0217	CcSEcCtD
Captopril—Loss of consciousness—Metformin—polycystic ovary syndrome	0.000373	0.0216	CcSEcCtD
Captopril—ABCB1—uterus—polycystic ovary syndrome	0.000364	0.00206	CbGeAlD
Captopril—Myalgia—Metformin—polycystic ovary syndrome	0.000361	0.0209	CcSEcCtD
Captopril—Chest pain—Metformin—polycystic ovary syndrome	0.000361	0.0209	CcSEcCtD
Captopril—Discomfort—Metformin—polycystic ovary syndrome	0.000357	0.0207	CcSEcCtD
Captopril—ABCB1—pituitary gland—polycystic ovary syndrome	0.000357	0.00203	CbGeAlD
Captopril—ABCB1—adipose tissue—polycystic ovary syndrome	0.000356	0.00202	CbGeAlD
Captopril—Shock—Metformin—polycystic ovary syndrome	0.000341	0.0198	CcSEcCtD
Captopril—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.000339	0.0197	CcSEcCtD
Captopril—Anorexia—Metformin—polycystic ovary syndrome	0.00033	0.0191	CcSEcCtD
Captopril—Hypotension—Metformin—polycystic ovary syndrome	0.000324	0.0188	CcSEcCtD
Captopril—ABCB1—adrenal gland—polycystic ovary syndrome	0.000319	0.00181	CbGeAlD
Captopril—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.000316	0.0183	CcSEcCtD
Captopril—Paraesthesia—Metformin—polycystic ovary syndrome	0.000311	0.018	CcSEcCtD
Captopril—Dyspnoea—Metformin—polycystic ovary syndrome	0.000309	0.0179	CcSEcCtD
Captopril—Somnolence—Metformin—polycystic ovary syndrome	0.000308	0.0179	CcSEcCtD
Captopril—Dyspepsia—Metformin—polycystic ovary syndrome	0.000305	0.0177	CcSEcCtD
Captopril—Decreased appetite—Metformin—polycystic ovary syndrome	0.000301	0.0175	CcSEcCtD
Captopril—Fatigue—Metformin—polycystic ovary syndrome	0.000299	0.0173	CcSEcCtD
Captopril—ABCB1—female gonad—polycystic ovary syndrome	0.000297	0.00169	CbGeAlD
Captopril—Constipation—Metformin—polycystic ovary syndrome	0.000296	0.0172	CcSEcCtD
Captopril—ABCB1—vagina—polycystic ovary syndrome	0.000296	0.00168	CbGeAlD
Captopril—Feeling abnormal—Metformin—polycystic ovary syndrome	0.000286	0.0165	CcSEcCtD
Captopril—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.000283	0.0164	CcSEcCtD
Captopril—ABCB1—endocrine gland—polycystic ovary syndrome	0.000277	0.00157	CbGeAlD
Captopril—Abdominal pain—Metformin—polycystic ovary syndrome	0.000274	0.0159	CcSEcCtD
Captopril—Asthenia—Metformin—polycystic ovary syndrome	0.000249	0.0144	CcSEcCtD
Captopril—Pruritus—Metformin—polycystic ovary syndrome	0.000245	0.0142	CcSEcCtD
Captopril—Diarrhoea—Metformin—polycystic ovary syndrome	0.000237	0.0137	CcSEcCtD
Captopril—Dizziness—Metformin—polycystic ovary syndrome	0.000229	0.0133	CcSEcCtD
Captopril—Vomiting—Metformin—polycystic ovary syndrome	0.00022	0.0128	CcSEcCtD
Captopril—Rash—Metformin—polycystic ovary syndrome	0.000218	0.0127	CcSEcCtD
Captopril—Dermatitis—Metformin—polycystic ovary syndrome	0.000218	0.0126	CcSEcCtD
Captopril—Headache—Metformin—polycystic ovary syndrome	0.000217	0.0126	CcSEcCtD
Captopril—Nausea—Metformin—polycystic ovary syndrome	0.000206	0.0119	CcSEcCtD
Captopril—MMP9—Signaling Pathways—ADRB3—polycystic ovary syndrome	5.28e-05	0.000267	CbGpPWpGaD
Captopril—CYP2D6—Biological oxidations—CYP19A1—polycystic ovary syndrome	5.24e-05	0.000264	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—LHB—polycystic ovary syndrome	5.22e-05	0.000263	CbGpPWpGaD
Captopril—SLC22A6—Transmembrane transport of small molecules—PLAT—polycystic ovary syndrome	5.18e-05	0.000262	CbGpPWpGaD
Captopril—CYP2D6—Metapathway biotransformation—CYP19A1—polycystic ovary syndrome	5.17e-05	0.000261	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—AKT2—polycystic ovary syndrome	5.14e-05	0.00026	CbGpPWpGaD
Captopril—MMP2—Developmental Biology—VEGFA—polycystic ovary syndrome	5.13e-05	0.000259	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—GNRH1—polycystic ovary syndrome	5.1e-05	0.000257	CbGpPWpGaD
Captopril—ALB—Hemostasis—RACGAP1—polycystic ovary syndrome	5.1e-05	0.000257	CbGpPWpGaD
Captopril—F2—Signaling Pathways—PDE3B—polycystic ovary syndrome	5.08e-05	0.000257	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—AR—polycystic ovary syndrome	4.97e-05	0.000251	CbGpPWpGaD
Captopril—MMP2—Axon guidance—IL6—polycystic ovary syndrome	4.97e-05	0.000251	CbGpPWpGaD
Captopril—F2—GPCR downstream signaling—GHRL—polycystic ovary syndrome	4.96e-05	0.00025	CbGpPWpGaD
Captopril—F2—Platelet activation, signaling and aggregation—VEGFA—polycystic ovary syndrome	4.94e-05	0.000249	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—AKR1C1—polycystic ovary syndrome	4.94e-05	0.000249	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—SCT—polycystic ovary syndrome	4.89e-05	0.000247	CbGpPWpGaD
Captopril—ALB—SLC-mediated transmembrane transport—SLC2A4—polycystic ovary syndrome	4.85e-05	0.000245	CbGpPWpGaD
Captopril—SLC22A6—Transmembrane transport of small molecules—SLC2A4—polycystic ovary syndrome	4.74e-05	0.000239	CbGpPWpGaD
Captopril—MMP9—Axon guidance—VEGFA—polycystic ovary syndrome	4.71e-05	0.000238	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—HSD3B1—polycystic ovary syndrome	4.71e-05	0.000238	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—MTNR1B—polycystic ovary syndrome	4.66e-05	0.000235	CbGpPWpGaD
Captopril—F2—Signaling Pathways—FSHR—polycystic ovary syndrome	4.63e-05	0.000234	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—FGF18—polycystic ovary syndrome	4.58e-05	0.000231	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—RBP4—polycystic ovary syndrome	4.54e-05	0.000229	CbGpPWpGaD
Captopril—F2—GPCR ligand binding—POMC—polycystic ovary syndrome	4.53e-05	0.000229	CbGpPWpGaD
Captopril—ABCB1—HIF-1-alpha transcription factor network—VEGFA—polycystic ovary syndrome	4.52e-05	0.000228	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—GHRL—polycystic ovary syndrome	4.5e-05	0.000227	CbGpPWpGaD
Captopril—ALB—Metabolism—NMNAT3—polycystic ovary syndrome	4.5e-05	0.000227	CbGpPWpGaD
Captopril—ALB—Platelet degranulation—VEGFA—polycystic ovary syndrome	4.42e-05	0.000223	CbGpPWpGaD
Captopril—ALB—Vitamin B12 Metabolism—IL6—polycystic ovary syndrome	4.38e-05	0.000221	CbGpPWpGaD
Captopril—F2—Signaling Pathways—RACGAP1—polycystic ovary syndrome	4.35e-05	0.00022	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—LHB—polycystic ovary syndrome	4.29e-05	0.000217	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—YAP1—polycystic ovary syndrome	4.24e-05	0.000214	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—BAX—polycystic ovary syndrome	4.24e-05	0.000214	CbGpPWpGaD
Captopril—F2—Signaling Pathways—ADRA1A—polycystic ovary syndrome	4.23e-05	0.000214	CbGpPWpGaD
Captopril—CYP2D6—Biological oxidations—CYP1A1—polycystic ovary syndrome	4.22e-05	0.000213	CbGpPWpGaD
Captopril—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—polycystic ovary syndrome	4.21e-05	0.000213	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—HSD3B2—polycystic ovary syndrome	4.19e-05	0.000212	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—GAB1—polycystic ovary syndrome	4.18e-05	0.000211	CbGpPWpGaD
Captopril—CYP2D6—Metapathway biotransformation—CYP1A1—polycystic ovary syndrome	4.17e-05	0.00021	CbGpPWpGaD
Captopril—F2—Signaling Pathways—FST—polycystic ovary syndrome	4.13e-05	0.000208	CbGpPWpGaD
Captopril—ALB—Metabolism—LPCAT2—polycystic ovary syndrome	4.11e-05	0.000208	CbGpPWpGaD
Captopril—ALB—Metabolism—SUOX—polycystic ovary syndrome	4.11e-05	0.000208	CbGpPWpGaD
Captopril—F2—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	4.1e-05	0.000207	CbGpPWpGaD
Captopril—F2—Signaling Pathways—ADRB3—polycystic ovary syndrome	4.08e-05	0.000206	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—AKR1C1—polycystic ovary syndrome	4.06e-05	0.000205	CbGpPWpGaD
Captopril—F2—Signaling Pathways—LHB—polycystic ovary syndrome	4.03e-05	0.000203	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—INSR—polycystic ovary syndrome	4e-05	0.000202	CbGpPWpGaD
Captopril—SLC22A6—Transmembrane transport of small molecules—GNAS—polycystic ovary syndrome	3.98e-05	0.000201	CbGpPWpGaD
Captopril—ABCB1—Metabolism—NMNAT3—polycystic ovary syndrome	3.94e-05	0.000199	CbGpPWpGaD
Captopril—F2—Signaling Pathways—GNRH1—polycystic ovary syndrome	3.94e-05	0.000199	CbGpPWpGaD
Captopril—ABCB1—Allograft Rejection—VEGFA—polycystic ovary syndrome	3.91e-05	0.000197	CbGpPWpGaD
Captopril—F2—Hemostasis—IGF1—polycystic ovary syndrome	3.9e-05	0.000197	CbGpPWpGaD
Captopril—F2—Hemostasis—AKT2—polycystic ovary syndrome	3.9e-05	0.000197	CbGpPWpGaD
Captopril—ALB—Metabolism—ISYNA1—polycystic ovary syndrome	3.83e-05	0.000193	CbGpPWpGaD
Captopril—F2—Signaling Pathways—AKR1C1—polycystic ovary syndrome	3.81e-05	0.000192	CbGpPWpGaD
Captopril—F2—GPCR downstream signaling—GNAS—polycystic ovary syndrome	3.8e-05	0.000192	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—AKR1C3—polycystic ovary syndrome	3.8e-05	0.000192	CbGpPWpGaD
Captopril—F2—Signaling Pathways—SCT—polycystic ovary syndrome	3.77e-05	0.000191	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—TNRC6B—polycystic ovary syndrome	3.74e-05	0.000189	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—SULT2A1—polycystic ovary syndrome	3.74e-05	0.000189	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—ADRB2—polycystic ovary syndrome	3.73e-05	0.000188	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—NMNAT3—polycystic ovary syndrome	3.71e-05	0.000188	CbGpPWpGaD
Captopril—F2—Metabolism of proteins—LEP—polycystic ovary syndrome	3.71e-05	0.000187	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—PGR—polycystic ovary syndrome	3.7e-05	0.000187	CbGpPWpGaD
Captopril—F2—Hemostasis—SERPINE1—polycystic ovary syndrome	3.7e-05	0.000187	CbGpPWpGaD
Captopril—ABCB1—Metabolism—LPCAT2—polycystic ovary syndrome	3.61e-05	0.000182	CbGpPWpGaD
Captopril—ABCB1—Metabolism—SUOX—polycystic ovary syndrome	3.61e-05	0.000182	CbGpPWpGaD
Captopril—F2—Signaling Pathways—MTNR1B—polycystic ovary syndrome	3.6e-05	0.000182	CbGpPWpGaD
Captopril—ALB—Folate Metabolism—IL6—polycystic ovary syndrome	3.57e-05	0.00018	CbGpPWpGaD
Captopril—MMP2—Developmental Biology—IL6—polycystic ovary syndrome	3.55e-05	0.000179	CbGpPWpGaD
Captopril—F2—Signaling Pathways—FGF18—polycystic ovary syndrome	3.54e-05	0.000179	CbGpPWpGaD
Captopril—F2—Signaling Pathways—RBP4—polycystic ovary syndrome	3.51e-05	0.000177	CbGpPWpGaD
Captopril—F2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—polycystic ovary syndrome	3.49e-05	0.000176	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—YAP1—polycystic ovary syndrome	3.49e-05	0.000176	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—GNAS—polycystic ovary syndrome	3.46e-05	0.000174	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—GHRL—polycystic ovary syndrome	3.44e-05	0.000174	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—PLAT—polycystic ovary syndrome	3.44e-05	0.000174	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—LPCAT2—polycystic ovary syndrome	3.4e-05	0.000171	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—SUOX—polycystic ovary syndrome	3.4e-05	0.000171	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—VEGFA—polycystic ovary syndrome	3.36e-05	0.00017	CbGpPWpGaD
Captopril—ABCB1—Metabolism—ISYNA1—polycystic ovary syndrome	3.35e-05	0.000169	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—CYP11A1—polycystic ovary syndrome	3.31e-05	0.000167	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—ATF1—polycystic ovary syndrome	3.29e-05	0.000166	CbGpPWpGaD
Captopril—F2—Signaling Pathways—YAP1—polycystic ovary syndrome	3.28e-05	0.000165	CbGpPWpGaD
Captopril—MMP9—Axon guidance—IL6—polycystic ovary syndrome	3.26e-05	0.000165	CbGpPWpGaD
Captopril—ALB—Metabolism—AKR1C2—polycystic ovary syndrome	3.25e-05	0.000164	CbGpPWpGaD
Captopril—ALB—Metabolism—TEAD2—polycystic ovary syndrome	3.25e-05	0.000164	CbGpPWpGaD
Captopril—F2—Signaling Pathways—GAB1—polycystic ovary syndrome	3.23e-05	0.000163	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—TCF7L2—polycystic ovary syndrome	3.2e-05	0.000162	CbGpPWpGaD
Captopril—F2—Metabolism of proteins—POMC—polycystic ovary syndrome	3.19e-05	0.000161	CbGpPWpGaD
Captopril—F2—Metabolism of proteins—INS—polycystic ovary syndrome	3.17e-05	0.00016	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—ISYNA1—polycystic ovary syndrome	3.16e-05	0.000159	CbGpPWpGaD
Captopril—CYP2D6—Biological oxidations—POMC—polycystic ovary syndrome	3.15e-05	0.000159	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—AKR1C3—polycystic ovary syndrome	3.13e-05	0.000158	CbGpPWpGaD
Captopril—ALB—Hemostasis—PLAT—polycystic ovary syndrome	3.11e-05	0.000157	CbGpPWpGaD
Captopril—F2—Signaling Pathways—INSR—polycystic ovary syndrome	3.09e-05	0.000156	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—CYP17A1—polycystic ovary syndrome	3.08e-05	0.000155	CbGpPWpGaD
Captopril—F2—Metabolism of proteins—IGF1—polycystic ovary syndrome	3.07e-05	0.000155	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—NGFR—polycystic ovary syndrome	3.03e-05	0.000153	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—PRL—polycystic ovary syndrome	3.01e-05	0.000152	CbGpPWpGaD
Captopril—ALB—Platelet activation, signaling and aggregation—IGF1—polycystic ovary syndrome	3e-05	0.000152	CbGpPWpGaD
Captopril—ALB—Platelet activation, signaling and aggregation—AKT2—polycystic ovary syndrome	3e-05	0.000151	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—polycystic ovary syndrome	2.96e-05	0.000149	CbGpPWpGaD
Captopril—F2—Signaling Pathways—AKR1C3—polycystic ovary syndrome	2.94e-05	0.000148	CbGpPWpGaD
Captopril—ALB—Transmembrane transport of small molecules—TFRC—polycystic ovary syndrome	2.9e-05	0.000146	CbGpPWpGaD
Captopril—F2—Signaling Pathways—TNRC6B—polycystic ovary syndrome	2.89e-05	0.000146	CbGpPWpGaD
Captopril—F2—Signaling Pathways—PGR—polycystic ovary syndrome	2.86e-05	0.000144	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—ADRB2—polycystic ovary syndrome	2.85e-05	0.000144	CbGpPWpGaD
Captopril—ALB—Platelet activation, signaling and aggregation—SERPINE1—polycystic ovary syndrome	2.85e-05	0.000144	CbGpPWpGaD
Captopril—ABCB1—Metabolism—AKR1C2—polycystic ovary syndrome	2.85e-05	0.000144	CbGpPWpGaD
Captopril—ABCB1—Metabolism—TEAD2—polycystic ovary syndrome	2.85e-05	0.000144	CbGpPWpGaD
Captopril—ALB—Selenium Micronutrient Network—IL6—polycystic ovary syndrome	2.83e-05	0.000143	CbGpPWpGaD
Captopril—ALB—Metabolism—PNPLA2—polycystic ovary syndrome	2.73e-05	0.000138	CbGpPWpGaD
Captopril—ALB—Transmembrane transport of small molecules—PLAT—polycystic ovary syndrome	2.69e-05	0.000136	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—TEAD2—polycystic ovary syndrome	2.69e-05	0.000136	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—AKR1C2—polycystic ovary syndrome	2.69e-05	0.000136	CbGpPWpGaD
Captopril—F2—Signaling Pathways—GHRL—polycystic ovary syndrome	2.66e-05	0.000134	CbGpPWpGaD
Captopril—F2—Signaling Pathways—PLAT—polycystic ovary syndrome	2.66e-05	0.000134	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—GNAS—polycystic ovary syndrome	2.64e-05	0.000133	CbGpPWpGaD
Captopril—ALB—Metabolism—SRD5A1—polycystic ovary syndrome	2.58e-05	0.00013	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—polycystic ovary syndrome	2.58e-05	0.00013	CbGpPWpGaD
Captopril—F2—GPCR downstream signaling—POMC—polycystic ovary syndrome	2.56e-05	0.000129	CbGpPWpGaD
Captopril—F2—Hemostasis—VEGFA—polycystic ovary syndrome	2.55e-05	0.000129	CbGpPWpGaD
Captopril—ABCB1—Transmembrane transport of small molecules—TFRC—polycystic ovary syndrome	2.54e-05	0.000128	CbGpPWpGaD
Captopril—F2—Signaling Pathways—ATF1—polycystic ovary syndrome	2.54e-05	0.000128	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—NCOR1—polycystic ovary syndrome	2.52e-05	0.000127	CbGpPWpGaD
Captopril—F2—Signaling Pathways—TCF7L2—polycystic ovary syndrome	2.47e-05	0.000125	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—NRG1—polycystic ovary syndrome	2.47e-05	0.000125	CbGpPWpGaD
Captopril—ALB—Metabolism—STAR—polycystic ovary syndrome	2.47e-05	0.000124	CbGpPWpGaD
Captopril—ALB—Transmembrane transport of small molecules—SLC2A4—polycystic ovary syndrome	2.46e-05	0.000124	CbGpPWpGaD
Captopril—F2—GPCR downstream signaling—AKT2—polycystic ovary syndrome	2.46e-05	0.000124	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	2.44e-05	0.000123	CbGpPWpGaD
Captopril—ALB—Hemostasis—GNAS—polycystic ovary syndrome	2.39e-05	0.000121	CbGpPWpGaD
Captopril—ABCB1—Metabolism—PNPLA2—polycystic ovary syndrome	2.39e-05	0.000121	CbGpPWpGaD
Captopril—ABCB1—Transmembrane transport of small molecules—PLAT—polycystic ovary syndrome	2.36e-05	0.000119	CbGpPWpGaD
Captopril—F2—Signaling Pathways—NGFR—polycystic ovary syndrome	2.34e-05	0.000118	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—POMC—polycystic ovary syndrome	2.33e-05	0.000117	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—IL6—polycystic ovary syndrome	2.33e-05	0.000117	CbGpPWpGaD
Captopril—F2—Signaling Pathways—PRL—polycystic ovary syndrome	2.32e-05	0.000117	CbGpPWpGaD
Captopril—ABCB1—Metabolism—SRD5A1—polycystic ovary syndrome	2.26e-05	0.000114	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—PNPLA2—polycystic ovary syndrome	2.25e-05	0.000114	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—AKT2—polycystic ovary syndrome	2.24e-05	0.000113	CbGpPWpGaD
Captopril—F2—Signaling Pathways—ADRB2—polycystic ovary syndrome	2.2e-05	0.000111	CbGpPWpGaD
Captopril—ALB—Metabolism—HMMR—polycystic ovary syndrome	2.2e-05	0.000111	CbGpPWpGaD
Captopril—ABCB1—Metabolism—STAR—polycystic ovary syndrome	2.16e-05	0.000109	CbGpPWpGaD
Captopril—ABCB1—Transmembrane transport of small molecules—SLC2A4—polycystic ovary syndrome	2.16e-05	0.000109	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—SRD5A1—polycystic ovary syndrome	2.13e-05	0.000108	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—IRS2—polycystic ovary syndrome	2.12e-05	0.000107	CbGpPWpGaD
Captopril—ALB—Metabolism—HSD3B1—polycystic ovary syndrome	2.1e-05	0.000106	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—LEP—polycystic ovary syndrome	2.07e-05	0.000105	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	2.07e-05	0.000105	CbGpPWpGaD
Captopril—ALB—Transmembrane transport of small molecules—GNAS—polycystic ovary syndrome	2.07e-05	0.000104	CbGpPWpGaD
Captopril—F2—Signaling Pathways—GNAS—polycystic ovary syndrome	2.04e-05	0.000103	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—STAR—polycystic ovary syndrome	2.04e-05	0.000103	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	1.96e-05	9.91e-05	CbGpPWpGaD
Captopril—ALB—Platelet activation, signaling and aggregation—VEGFA—polycystic ovary syndrome	1.96e-05	9.9e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.94e-05	9.81e-05	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—polycystic ovary syndrome	1.93e-05	9.74e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—HMMR—polycystic ovary syndrome	1.93e-05	9.72e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—LHB—polycystic ovary syndrome	1.91e-05	9.65e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—NRG1—polycystic ovary syndrome	1.91e-05	9.63e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—HSD3B2—polycystic ovary syndrome	1.87e-05	9.43e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—IRS1—polycystic ovary syndrome	1.85e-05	9.33e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—HSD3B1—polycystic ovary syndrome	1.84e-05	9.27e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—HMMR—polycystic ovary syndrome	1.81e-05	9.16e-05	CbGpPWpGaD
Captopril—ABCB1—Transmembrane transport of small molecules—GNAS—polycystic ovary syndrome	1.81e-05	9.15e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—AKR1C1—polycystic ovary syndrome	1.81e-05	9.13e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—POMC—polycystic ovary syndrome	1.78e-05	8.98e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—INS—polycystic ovary syndrome	1.77e-05	8.94e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—HSD3B1—polycystic ovary syndrome	1.73e-05	8.74e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—IGF1—polycystic ovary syndrome	1.71e-05	8.64e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—AKT2—polycystic ovary syndrome	1.71e-05	8.64e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—LHB—polycystic ovary syndrome	1.67e-05	8.45e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—SULT2A1—polycystic ovary syndrome	1.67e-05	8.41e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—HSD3B2—polycystic ovary syndrome	1.64e-05	8.26e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—IRS2—polycystic ovary syndrome	1.63e-05	8.25e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.63e-05	8.21e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—RRM2—polycystic ovary syndrome	1.61e-05	8.14e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—LEP—polycystic ovary syndrome	1.6e-05	8.08e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—AKR1C1—polycystic ovary syndrome	1.59e-05	8e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—LHB—polycystic ovary syndrome	1.58e-05	7.97e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—YAP1—polycystic ovary syndrome	1.55e-05	7.85e-05	CbGpPWpGaD
Captopril—ALB—Hemostasis—IGF1—polycystic ovary syndrome	1.55e-05	7.81e-05	CbGpPWpGaD
Captopril—ALB—Hemostasis—AKT2—polycystic ovary syndrome	1.55e-05	7.8e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—HSD3B2—polycystic ovary syndrome	1.54e-05	7.79e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—AKR1C1—polycystic ovary syndrome	1.49e-05	7.54e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—NAMPT—polycystic ovary syndrome	1.49e-05	7.54e-05	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	1.48e-05	7.49e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—CYP11A1—polycystic ovary syndrome	1.47e-05	7.45e-05	CbGpPWpGaD
Captopril—ALB—Hemostasis—SERPINE1—polycystic ovary syndrome	1.47e-05	7.42e-05	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	1.46e-05	7.39e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—SULT2A1—polycystic ovary syndrome	1.46e-05	7.36e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—IRS1—polycystic ovary syndrome	1.43e-05	7.2e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—RRM2—polycystic ovary syndrome	1.41e-05	7.13e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—AKR1C3—polycystic ovary syndrome	1.39e-05	7.03e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—SULT2A1—polycystic ovary syndrome	1.37e-05	6.94e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—POMC—polycystic ovary syndrome	1.37e-05	6.94e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—CYP17A1—polycystic ovary syndrome	1.37e-05	6.92e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—INS—polycystic ovary syndrome	1.37e-05	6.9e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—YAP1—polycystic ovary syndrome	1.36e-05	6.88e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—RRM2—polycystic ovary syndrome	1.33e-05	6.72e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—IGF1—polycystic ovary syndrome	1.32e-05	6.67e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—AKT2—polycystic ovary syndrome	1.32e-05	6.67e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—NAMPT—polycystic ovary syndrome	1.31e-05	6.61e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—CYP11A1—polycystic ovary syndrome	1.29e-05	6.52e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—YAP1—polycystic ovary syndrome	1.28e-05	6.48e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.26e-05	6.34e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—NAMPT—polycystic ovary syndrome	1.23e-05	6.22e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—AKR1C3—polycystic ovary syndrome	1.22e-05	6.16e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—CYP11A1—polycystic ovary syndrome	1.22e-05	6.15e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—CYP17A1—polycystic ovary syndrome	1.2e-05	6.06e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—TH—polycystic ovary syndrome	1.19e-05	5.99e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—SLC2A4—polycystic ovary syndrome	1.15e-05	5.83e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—AKR1C3—polycystic ovary syndrome	1.15e-05	5.81e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—CYP17A1—polycystic ovary syndrome	1.13e-05	5.71e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.12e-05	5.65e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—CYP19A1—polycystic ovary syndrome	1.09e-05	5.48e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—TH—polycystic ovary syndrome	1.04e-05	5.25e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—SLC2A4—polycystic ovary syndrome	1.01e-05	5.1e-05	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—IL6—polycystic ovary syndrome	1.01e-05	5.1e-05	CbGpPWpGaD
Captopril—ALB—Hemostasis—VEGFA—polycystic ovary syndrome	1.01e-05	5.1e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—TH—polycystic ovary syndrome	9.8e-06	4.94e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—GNAS—polycystic ovary syndrome	9.69e-06	4.89e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—SLC2A4—polycystic ovary syndrome	9.53e-06	4.81e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—CYP19A1—polycystic ovary syndrome	9.51e-06	4.8e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—NCOR1—polycystic ovary syndrome	9.23e-06	4.66e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—CYP19A1—polycystic ovary syndrome	8.96e-06	4.52e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—CYP1A1—polycystic ovary syndrome	8.75e-06	4.42e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—VEGFA—polycystic ovary syndrome	8.63e-06	4.36e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—GNAS—polycystic ovary syndrome	8.49e-06	4.28e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—MTHFR—polycystic ovary syndrome	8.15e-06	4.12e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—NCOR1—polycystic ovary syndrome	8.08e-06	4.08e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—GNAS—polycystic ovary syndrome	8e-06	4.04e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—IL6—polycystic ovary syndrome	7.73e-06	3.9e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—CYP1A1—polycystic ovary syndrome	7.66e-06	3.87e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—NCOR1—polycystic ovary syndrome	7.62e-06	3.85e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—CYP1A1—polycystic ovary syndrome	7.22e-06	3.65e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—MTHFR—polycystic ovary syndrome	7.14e-06	3.61e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—MTHFR—polycystic ovary syndrome	6.73e-06	3.4e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—PPARG—polycystic ovary syndrome	6.61e-06	3.34e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—POMC—polycystic ovary syndrome	6.52e-06	3.29e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—INS—polycystic ovary syndrome	6.49e-06	3.27e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—IL6—polycystic ovary syndrome	5.97e-06	3.01e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—PPARG—polycystic ovary syndrome	5.79e-06	2.92e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—POMC—polycystic ovary syndrome	5.71e-06	2.88e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—INS—polycystic ovary syndrome	5.68e-06	2.87e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—PPARG—polycystic ovary syndrome	5.46e-06	2.76e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—POMC—polycystic ovary syndrome	5.38e-06	2.72e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—INS—polycystic ovary syndrome	5.35e-06	2.7e-05	CbGpPWpGaD
